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Glucose hypometabolism is a prominent feature of
the brains of patients with Alzheimer’s disease (AD).
Disease progression is associated with a reduction
in glucose transporters in both neurons and endothe-
lial cells of the blood-brain barrier. However, whether
increasing glucose transport into either of these cell
types offers therapeutic potential remains unknown.
Using an adult-onset Drosophila model of Ab (amy-
loid beta) toxicity, we show that genetic overex-
pression of a glucose transporter, specifically in neu-
rons, rescues lifespan, behavioral phenotypes, and
neuronalmorphology. This ameliorationofAb toxicity
is associated with a reduction in the protein levels of
the unfolded protein response (UPR) negativemaster
regulator Grp78 and an increase in the UPR. We
further demonstrate that genetic downregulation of
Grp78 activity also protects against Ab toxicity, con-
firming a causal effect of its alteration on AD-related
pathology. Metformin, a drug that stimulates glucose
uptake in cells, mimicked these effects, with a
concomitant reduction in Grp78 levels and rescue of
theshortened lifespanandclimbingdefectsofAb-ex-
pressing flies. Our findings demonstrate a protective
effect of increased neuronal uptake of glucose
against Ab toxicity and highlight Grp78 as a novel
therapeutic target for the treatment of AD.
INTRODUCTION
46.8 million people live with dementia worldwide [1], with Alz-
heimer’s disease (AD) being the most common type. Prevalence
continues to rise with increasing life expectancy. Currently there
are no cures, and there is an urgent need to identify ways of pre-
venting or modifying disease progression. AD is thought to be
triggered by the accumulation of extracellular Ab (amyloid
beta) peptides, derived from the misprocessing of amyloid pre-
cursor protein (APP) [2], leading to cellular stress, accumulation
of toxic intracellular Tau, and eventual neuronal cell death [2].
However, recent evidence suggests that Ab might also poten-
tially play a protective, antimicrobial role [3].Current Biology 26, 2291–2300, Septemb
This is an open access article undA prominent feature of AD progression is a substantial reduc-
tion in glucose metabolism [4]. This drop precedes the onset of
clinical symptoms [4], worsens with disease progression [4],
and is a more accurate marker of neuronal atrophy than is Ab
accumulation itself [5]. Patients with type 2 diabetes, who are
at higher risk of AD, display increased insulin resistance, which
has been linked both to reduced glucose uptake in the brain
and to memory impairments [6]. Mouse models of AD also
show a decrease in glucose metabolism, suggesting that it
may be part of the disease process [7]. However, the exact
role of lowered glucose metabolism in disease progression is
unknown.
Glucose does not freely cross cell membranes and is, instead,
actively shuttled by transporters. In humans, there are 12
glucose transporters, with different expression patterns and
affinities. In the brain, Glut1 is expressedmainly in glia and endo-
thelial cells, whereas Glut3 is expressed in neurons [7]. A reduc-
tion in expression of a number of glucose transporters has been
observed in the brains of mouse AD models [8] and of human
patients [7]. The timing of this decrease correlates with increases
in Tau phosphorylation and neurofibrillary tangles (NFTs) [7]. In a
mouse model of AD pathogenesis, a reduction in neuronal Glut3
expression coincided with a reduction in glucosemetabolism [8],
while a drop in Glut1 in endothelial cells exacerbated pathology
in another mouse AD model [9].
Whether impaired neuronal glucose metabolism plays a
causal role in neurodegeneration in AD awaits investigation.
The drop in glucose metabolism could contribute to disease
progression in several ways. It could lead to a reduction in
ATP in neurons, since glucose is the main source of energy.
Downregulation of the hexosamine pathway, which relies on
glucose for GlcNAc production, would lead to a reduction in
Tau GlcNAcylation, which, in turn, could drive up toxic Tau phos-
phorylation, since the two are negatively correlated [10]. Hypo-
metabolism and glucose deprivation have been shown to induce
the unfolded protein response (UPR) [11]; this, too, could drive
Tau phosphorylation [11]. Any or all of these mechanisms could
contribute to neurodegeneration.
To begin to experimentally test the role of glucose transport
and metabolism in AD pathogenesis, we used a model of Ab
toxicity in the fruit fly Drosophila melanogaster [12]. Drosophila
has proved to be an excellent model system in which to study
neurodegenerative diseases. The fly has a distinct brain struc-
ture with cell types analogous to the human brain, as well as a
blood-brain barrier (BBB), and is, therefore, ideal for studyinger 12, 2016 ª 2016 The Author(s). Published by Elsevier Ltd. 2291
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
the neurodegenerative process in a complex tissue. The meta-
bolic coupling between glia and neurons observed inmammalian
brains is also conserved in flies [13]. The fly AD model that we
used expresses pathogenic Arctic Ab42 tagged with an endo-
plasmic reticulum (ER) export signal peptide [14] exclusively in
the neurons of the adult fly, thereby removing any confounding
developmental effects. These flies have shortened lifespans,
behavioral defects, and neurodegeneration [12].
If lowered glucose metabolism in neurons is part of the patho-
genic cascade from toxic Ab, then experimentally increasing
glucose metabolism in neurons should ameliorate the pathogen-
esis in the AD model. Therefore, we assessed the effect of over-
expressing a glucose transporter, Glut1, in the neurons of the AD
flies. We found that this partially rescued the Ab phenotypes,
without affecting the expression level of the toxic Ab peptide.
Glut1 overexpression led to downregulation of the expression
of Grp78 (glucose-regulated protein 78/BiP), the negativemaster
regulator of the UPR. This, in turn, increased the UPR, in associ-
ation with an improvement in protein homeostasis. Interestingly,
feeding the flies the drug metformin, which increases glucose
transport, also caused a drop in Grp78 levels and an increase
in lifespan, suggesting a possible pharmacological therapeutic
avenue.
RESULTS
Drosophila melanogaster has two glucose transporters: Glut1
and Glut3. Glut3 is expressed only in testes, while Glut1 is ex-
pressed ubiquitously [15]. In order to increase glucose meta-
bolism, we cloned Glut1 under the control of the UAS (upstream
activating sequence) promoter and drove its expression with a
constitutive and ubiquitous daGal4 driver. This led to increased
uptake of a glucose analog (Figure S1A), demonstrating that
increased Glut1 expression can, indeed, increase transport of
glucose into cells.
Next, we overexpressed Glut1 in the neurons of adult flies,
using an inducible elavGS (elav-GeneSwitch-Gal4) driver and
confirmed the overexpression by qPCR in fly heads (Fig-
ure S1B). Overexpression of Glut1 had no effect on the lifespan
of wild-type flies (Figure S1C), but it increased lifespan in
Arctic-Ab42(Ab)-expressing flies (Figure 1A) and slowed their
decline in climbing ability, a behavioral measure of neuronal
health (Figure 1B). Interestingly, the climbing ability of flies ex-
pressing Ab and Glut1 was worse than that of flies expressing
Ab alone at early time points, possibly suggesting that Glut1
expression could impair climbing ability in early life, before its
beneficial effect on disease development takes effect (Fig-
ure 1B). Sleep pattern, too, is directly controlled by neuronal
activity. Flies are diurnal, sleeping mainly at night. Expression
of Ab rendered the flies more arrhythmic, with fewer flies
showing a clear change in sleep pattern between day and
night, largely as a consequence of a substantial increase in
day sleep (Figure 1C). The Ab flies also spent more total time
sleeping than did non-induced controls (Figure 1C). Overex-
pression of Glut rescued this pattern, with the flies partially
recovering their diurnal sleep pattern and spending less total
time sleeping (Figure 1C). To confirm that the phenotypic
rescue of the Ab toxicity was, indeed, due to increased glucose
uptake and not some other activity of Glut1, we checked2292 Current Biology 26, 2291–2300, September 12, 2016whether altering sugar concentration in the food could modu-
late the Glut1 rescue of lifespan in Ab-expressing flies (Fig-
ure S1D). We found that reducing dietary sugar intake differen-
tially affected the lifespans of flies expressing Ab alone, relative
to the flies expressing Ab and Glut1, with no rescue of lifespan
by Glut 1 at the lowest sugar concentration of 2.5%. As the
sugar in the food was reduced, so did the lifespan extension af-
forded by Glut1. This suggests that the phenotypic rescue is
linked to an increased uptake of sugar.
To determine whether Glut1 could rescue neurodegeneration
after adult induction of Ab, we marked a sub-population of neu-
rons with Tomato driven by the Q system [16], using nSyb-
QF2 > Tomato [17], which marks a set of neurons in the central
portion of the Drosophila brain (Figure 1D) while, at the same
time, driving Ab pan-neuronally with the UAS system. The two
misexpression systems are independent of each other, and we
could thusmonitor themorphologyofasub-populationofneurons
in the presence of Ab and of overexpression of Glut1. When Ab
was expressed, a number of filamentous structures clearly visible
in the wild-type brain were lost, reflecting the degeneration of
axons or dendrites. Strikingly, when Glut1 was overexpressed,
the neuronal morphology was completely restored (Figure 1D).
Surprisingly, Glut1 overexpression did not affect Ab protein or
mRNA levels in heads (Figures 1E and 1F), suggesting that Glut1
reduced the toxicity, rather than the total load, of Ab.
In humans and mouse models of AD, disease progression has
been linked to a decrease in glucose transporters [8], and in
mouse AD models, a reduction of glucose transporters in endo-
thelial cells exacerbates disease development. Similarly, in our
Drosophilamodel, RNAi of Glut1 in neurons (Figure S1E) reduced
the lifespan of Ab-expressing flies, indicating that reduction of
glucose import into neurons worsens Ab toxicity, similar to the
mechanism suggested in humans.
In both mammalian and fly brains under normal physiological
conditions, glycolysis occurs primarily in glia [13]. Therefore,
we assessed whether increasing glucose uptake in glia could
also affect pathology. For this, we generated a fly model
concomitantly expressing Ab in neurons and Glut1 in glia. Ab
was driven in neurons by the nSyb-QF2 driver [17], which was
induced starting from eclosion, whereas Glut1 was induced by
the constitutive glial driver repo-Gal4. Overexpression of Glut1
in glia did not rescue the toxicity of neuronal Ab, as assessed
by lifespan (Figure S1F). Hence, either the Ab toxicity in neurons
was too great for the induction of Glut1 that we achieved to
rescue it, or Glut1 in glia cannot rescue Ab toxicity.
Glucose uptake can influence many cellular processes and
could, therefore, rescue Ab toxicity in several ways. The most
obvious candidate is energy metabolism, since glucose is the
source of most cellular energy. However, we did not observe
an obvious energy deficit in the brains of our Ab-expressing flies,
and the ADP/ATP ratio in brains was unchanged when Glut1 was
overexpressed (Figure S1G).
Next, we considered whether Glut1 overexpression reduced
Ab toxicity by acting through the hexosamine biosynthetic
pathway, by increasing protein GlcNAcylation. However, upre-
gulation in neurons of GFAT2, the first and rate-limiting enzyme
in the hexosamine biosynthetic pathway, shortened the lifespan
of the Ab-expressing flies (Figure S1H), contrary to what would
be predicted from this hypothesis.
AC
D
E F
B Figure 1. Glut1 Overexpression Rescues
Ab Toxicity
(A) Survival curves of flies expressing Ab or Ab
Glut1 in adult neurons (+RU) and uninduced
controls (-RU). p < 0.01, when comparing Ab +RU
and Ab Glut1 +RU by log-rank test.
(B) Climbing assay performance index of flies of
the same genotypes. p < 1E-10 when comparing
Ab response to RU relative to AbGlut response by
ordinal logistics regression.
(C). 24-hr sleep profile of 21-day-old flies ex-
pressing Ab or Ab Glut1 in neurons (+RU) and
uninduced controls (-RU) on day 3 in the LD cycle.
At the right, total sleep amount for females of each
genotype are shown (plotted as means ± SEM).
*p < 0.01; **p < 0.001; and ***p < 0.0001, by two-
way ANOVA. Genotypes: UAS Ab/UAS Glut1;
elavGS, UAS Ab; elavGS.
(D) Confocal images of brains of 21-day-old con-
trol flies (-RU) and flies expressing Ab or Ab Glut1
driven by elavGS (+RU). The nSyb-QF2 driver,
kept in an inactive state by the tub-QS repressor,
drives Tomato. Once flies eclosed, they were fed
QA, which binds QS to induce expression of
Tomato, thus labeling a subset of neurons.
Fluorescence intensity scores are plotted as
means ± SEM. *p < 0.05, by ANOVA (n = 3–4).
Genotypes: QUAS-mtdTomato-3xHA; nSybQF2
tubQS/elavGS, QUAS-mtdTomato-3xHA/UAS
Ab; elavGS/nSybQF2 tubQS, QUAS-mtdTomato-
3xHA/UAS Ab UAS Glut1; elavGS/nSybQF2
tubQS.
(E) Ab42 protein levels, measured by ELISA, in the
heads of 9-day-old flies expressing Ab or AbGlut1
in neurons (+RU) and uninduced controls (-RU),
plotted as means ± SEM (n = 3). ***p < 0.0001, by
ANOVA; ns, not significant.
(F) Ab42 mRNA levels (relative to eIF1A) in the
heads of similar 14-day-old flies, measured by
qPCR, plotted as means ± SEM (n = 4). ***p <
0.0001, by ANOVA; ns, not significant. Geno-
types: UAS Ab; elavGS, UAS Ab/UAS Glut1;
elavGS.
See also Figure S1.Glucose uptake can affect the UPR [18], which is becoming
increasingly recognized as important in neurodegenerative dis-
eases, including AD [19], although whether it plays a protective
or detrimental role remains unclear [19]. The UPR signaling
cascade is activated in response to ER stress, allowing the
cell either to restore protein homeostasis or to enter apoptosis
[19], and is mediated by three trans-membrane proteins:
pancreatic ER kinase (PERK), inositol-requiring enzyme 1
(IRE1), and activating transcription factor 6 (ATF6). Grp78, also
known as BiP, binds and keeps these three proteins in an inac-
tive state. Upon ER stress, Grp78 targets misfolded proteins to
act as a chaperone, and thus releases PERK, IRE1, and ATF6 to
activate a series of downstream cascades, leading to the phos-
phorylation of eIF2alpha and reduction of protein translation,
activation of downstream transcription factors such as ATF4
and Xbp1, and increases in chaperones such as Grp78 itself
(Figure S2A) [19].The main marker of PERK activation, eIF2alpha phosphoryla-
tion, was not affected by either Ab or Glut1 expression in neurons
(Figure 2A); however, we did confirm that the antibody we used
was able to detect eIF2alpha phosphorylation in response to
a strong UPR inducer (Figure S2B). However, Grp78 mRNA
expression, a marker of ATF6 activation, was increased in flies
expressing Ab (Figure 2B). Xbp1 splicing, a marker of IRE1 acti-
vation, increases in response to Ab in flies [20]. In our model, we
noticed a trend toward an increase in the fluorescence of a GFP
reporter for Xbp1 splicing, but this did not reach significance
(Figure 2C). However, when we measured the spliced Xbp1 iso-
form by qPCR, it was significantly increased in response to Ab
(Figure 2D), in agreement to what has previously been described
[20]. Ab thus induces the ATF6 and IRE1, but not the PERK,
branches of the UPR. Unexpectedly, co-expression of Glut1
increasedGrp78mRNA (Figure 2B) andXbp1 splicing (Figure 2C)
even further, suggesting an additional increase of the UPR inCurrent Biology 26, 2291–2300, September 12, 2016 2293
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Figure 2. UPR Components Activated in
Ab-Expressing Flies Are Induced Even
Further by Glut1 Overexpression
(A) Western blot of eIF2 phosphorylation levels in
heads of Ab- and AbGlut1-expressing flies (+RU)
and in controls (-RU), showing no significant dif-
ference. Bottom: plotted as means ± SEM (n = 3).
Top: a representative gel from the same samples.
(B) Grp78 mRNA levels in heads of 18-day-old flies
expressing Ab or Ab Glut1 in neurons (+RU) and
uninduced controls (-RU), measured by qPCR
(relative to eIF1A), plotted as means ± SEM. Ge-
notypes: UAS Ab; elavGS, UAS Ab/UAS Glut1;
elavGS.
(C) Quantification of GFP fluorescence in fly brains
expressing an Xbp1GFP splicing reporter, plotted
as means ± SEM (n = 6–13). Genotypes: elavGS/
UAS-Xbp1GFP, UAS Ab; elavGS/UAS-Xbp1GFP,
UAS Ab/UAS Glut1; elavGS/UAS-Xbp1GFP.
(D) Spliced Xbp1 mRNA levels in heads of 18-day-
old flies expressing Ab or Ab Glut1 in neurons
(+RU) and uninduced controls (-RU), measured by
qPCR (relative to eIF1A), plotted as means ± SEM
(E) Western blot of Grp78 in 14-day-old flies of the
same genotypes, plotted below as means ± SEM
(n = 6–16). The image is a representative gel of the
same samples. Genotypes: UAS Ab; elavGS, UAS
Ab/UAS Glut1; elavGS.
*p % 0.05; **p % 0.01, by ANOVA. See also Fig-
ure S2.response to glucose uptake. Grp78 protein levels are tightly
controlled at the level of translation [21], and an increase in the
mRNA, therefore, does not necessarily indicate higher protein
levels. Therefore, we measured Grp78 protein and found that it
also increased in the presence of Ab, albeit to a smaller extent
(Figure 2E). However, surprisingly, overexpression of Glut1 re-
sulted in reduced expression of Grp78 protein (Figure 2E), sug-
gesting that Glut1 and the increased glucose uptake that it
produced reduced either Grp78 translation or stability.
Grp78 is broadly considered a negative regulator of the UPR,
since it binds and maintains ATF6 and IRE1 in an inactive state.
Overexpression of Grp78 can attenuate UPR signaling both in
non-neuronal cells [22] and in neurons [19], and its knockdown
can lead to increased activation of the UPR upon ER stress
[23]. Our results point to a similar mechanism, with a drop in
Grp78 protein levels upon Glut1 expression leading to an in-
crease in ATF6 and IRE1 activity. Ab induced only the IRE1
and ATF6 branches of the UPR, similar to tunicamycin treatment
[24]. Therefore, we determined whether Glut1 overexpression2294 Current Biology 26, 2291–2300, September 12, 2016could also increase resistance to tuni-
camycin. Indeed, Glut1 overexpression
protected flies from tunicamycin stress
(Figure 3A), accompanied by a block in
Grp78 induction (Figure 3B) and a trend
toward a further increase in UPR markers
upon Glut1 expression (Figures 3C and
3D), similar to what was observed in the
Ab expressing brains. Glut1 could, there-
fore, protect against UPR stress, attribut-
able to a reduction in Grp78 levels.If Glut1 overexpression protects against Ab-induced UPR
stress by reducing Grp78 levels, then a reduction in Grp78 activ-
ity should also rescue Ab toxicity. We tested this by overexpress-
ing a dominant-negative version of Grp78, Grp78K97S, which
carries a point mutation affecting the coupling of ATP binding
to substrate release [25]. Expression of Grp78K97S in neurons
increased both the lifespan and the climbing ability of Ab-ex-
pressing flies (Figures 4A and 4B), suggesting that, indeed,
reduced Grp78 activity is causal in the amelioration of Ab toxicity
by Glut1.
AD is characterized by a deregulation of protein homeo-
stasis [26], which could contribute to disease. Therefore, we
hypothesized that increased glucose metabolism in neurons
allows the UPR to increase even further and, thus, to restore
protein homeostasis. To test this idea, we measured insol-
uble ubiquitinated protein levels in heads and found that Ab
expression led to the accumulation of insoluble ubiquitinated
proteins, which was abrogated by Glut1 overexpression (Fig-
ure 5), Glut1 overexpression, therefore, allowed neurons to
AC D
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Figure 3. Glut1 Protects Flies from Tunicamycin-Induced ER Stress
(A) Survival of Glut1-overexpressing flies on food containing tunicamycin (p < 0.05 for effect of Glut1 relative to driver-alone control by log-rank test).
(B) Western blot of Grp78 in whole flies after 48 hr on tunicamycin, plotted below as means ± SEM (n = 5–8); the image shows representative gels of similar
samples. *p% 0.05 by ANOVA.
(C) qPCR of Xbp1-spliced isoform levels (normalized to eIF1A), in flies treated for 48 hr with tunicamycin, plotted asmeans ± SEM (n = 3–4). **p% 0.01 by ANOVA.
(D) qPCR of Grp78 (normalized to eIF1A), in flies treated for 48 hr with tunicamycin, plotted as means ± SEM (n = 3–4). *p % 0.05; **p % 0.01, by ANOVA.
Genotypes: daGal4, UASGlut1; daGal4.re-establish protein homeostasis, presumably via upregulation
of the UPR.
Metformin is a drug used to treat type 2 diabetes, and it in-
creases glucose uptake in several tissues [27, 28] by increasing
the translocation of glucose transporters to the plasma mem-
brane [27]. Therefore, we treated our Ab-overexpressing flies
with metformin to determine whether we could recapitulate
the rescue observed by overexpressing Glut1. Indeed, feeding
Ab-overexpressing flies with a range of metformin concentra-
tions resulted in a significant lifespan extension (Figure 6A) and
increase in climbing ability (Figure 6B) without altering Ab levels
(Figure 6C). Interestingly, 80 mMmetformin reduced the lifespan
of flies that did not express Ab and was also less effective than
lower doses at extending the lifespan of Ab-expressing flies,
but it gave the strongest rescue of climbing ability. These results
suggest that this high concentration of metformin shows a bene-
ficial effect on neuronal-related health before 25 days but thatcontinuous exposure to a high dose of metformin leads, at later
ages, to systemic toxicity and reduced lifespan. The rescue was
dependent on Glut1 expression, since RNAi of Glut1 blocked the
lifespan extension frommetformin treatment (Figure 6D). Metfor-
min treatment, like Glut1 overexpression, also blocked the in-
crease inGrp78 levels associatedwith Ab expression (Figure 6E).
Metformin could, therefore, be a potential therapeutic modulator
of Ab pathology by blocking toxic Grp78 induction.
DISCUSSION
Glucosemetabolism has been strongly implicated the pathogen-
esis of AD [5, 7]. Patients display a marked reduction in glucose
metabolism in brain areas vulnerable to degeneration, and this
precedes the onset of clinical symptoms and mirrors disease
progression more closely than does Ab deposition [4]. Expres-
sion of neuronal glucose transporters also drops in AD patientsCurrent Biology 26, 2291–2300, September 12, 2016 2295
A B Figure 4. Grp78 Dominant-Negative Version
Rescues Ab Toxicity
(A) Lifespan survival curves of flies expressing
Ab or the Ab Grp78 dominant-negative version
in neurons (+RU) and uninduced controls (-RU).
(Ab+RUand AbGrp78 dominant-negative +RU are
different. p < 1E-13 by log rank).
(B) Climbing assay performance index for the same
flies plotted over time (p < 0.005 when comparing
Ab response to RU relative to Ab Grp78.K97S
response by ordinal logistics regression). Geno-
types:UASAb; elavGS,UASAb/UASGrp78.K97S;
elavGS.and in AD mouse models [7]. Recently, it was shown that reduc-
tion of glucose transport across the BBB in mouse AD models
exacerbates Ab toxicity [9]. However, whether impaired glucose
metabolism in neurons plays a causal role in AD pathogenesis
has not been addressed directly.
Our study has shown that experimentally increasing glucose
uptake in neurons can protect against Ab toxicity. In our
Drosophila AD model, Glut1 overexpression led to a lifespan
increase, an amelioration of phenotypes linked to neuronal
health—namely, climbing and sleep—and a restoration of normal
neuronal morphology. This improvement was associated with
a reduction in Grp78 protein levels and an upregulation of
the UPR.
In AD patients, the UPR is activated early in disease pathogen-
esis [11]. Similarly, Ab expression in the neurons of adult flies led
to the induction of the UPR. Grp78 levels were increased, simi-
larly to those of mice models of AD [29], of AD patients early in
disease development [30], and in neuronal cells derived from
AD patients’ induced pluripotent stem cells (iPSCs) [31].
Intriguingly, the rescue of Ab toxicity by Glut1 was associated
with a reduction in Grp78 expression. Grp78 is becoming an
increasingly important therapeutic target, especially in cancer
biology, where its inhibition increases cells’ susceptibility to
chemotherapy agents [32]. Its role in neurodegeneration is less
well defined. In rat models of Parkinson’s disease, activation of
Grp78 is protective [33], and its downregulation is detrimental
[34]. However, its role in AD models has not been tested. Our
studies suggest that Grp78 downregulation can ameliorate Ab
toxicity by allowing upregulation of the UPR. Already, it has
been shown in flies that overexpression of Xbp1 can ameliorate
Ab42 toxicity [20], supporting the idea that upregulation of UPR
components could be beneficial in AD models. The role of
Grp78 has not been tested in other models of neurodegenera-
tion, and a complex picture is emerging regarding the role of
downstream UPR effectors, where, depending on the precise
experimental conditions, upregulation of the UPR appears to
be protective or detrimental [19]. For example, downregulation
of PERK is protective in some ALS (amyotrophic lateral sclerosis)
or prion disease models, whereas increased Xbp1 can be pro-
tective in Parkinson’s and Huntington’s disease models [19].
This could be because the UPR is a complex pathway with
extensive crosstalk between the different signaling cascades,
so it would be difficult to predict reliably the outcome of an inter-
vention. Alternatively, a mild upregulation of the UPR could allow
the induction of an ER-hormetic response, increasing ER proteo-
stasis to allow a neuron to deal with an increase in misfolded2296 Current Biology 26, 2291–2300, September 12, 2016proteins, whereas, in other conditions, a strong induction of
the UPR could lead to apoptosis, and, therefore, blocking this
response could also increase neuronal survival [19].
How glucose regulates Grp78 expression is unclear. It is
well established that glucose starvation induces expression of
Grp78 [35], and, in one study, increased glucose reduced
Grp78 expression in cultured neurons [36]. However, little is
known about how physiological changes in glucose metabolism
modulate Grp78, and it will be important to identify the mecha-
nisms at work.
Our study suggests a model where Ab accumulation in the
brain induces the UPR, and increased glucose uptake in neurons
blocks the negative feedback loop linked to Grp78 upregulation,
resulting in even further increased UPR, which allows neurons
to clear insoluble ubiquitinated proteins and restore protein
homeostasis, resulting in the rescue of neurodegeneration and
increased lifespan. This mechanism of action could be relevant
to the benefits observed by administration of insulin nasal
spray in AD patients [37]. Insulin is thought to act via PI3K/
MAPK (phosphatidylinositol 3-kinase/mitogen-activated protein
kinase) to influence Ab trafficking and decrease Tau phosphory-
lation by inhibiting Gsk3 [38]. However, insulin can upregulate
glucose transporters in neurons [39] and increase glucose meta-
bolism [39]. It would be interesting to determine whether insulin
administration also upregulates the UPR.
Glucosemetabolism has also been implicated in the increased
risk of AD associated with type 2 diabetes. The link is well estab-
lished, but the mechanism is less so [40]; possibilities include
increased vascular risk factors associated with metabolic syn-
drome in type 2 diabetes, as well as hyperglycemia-linked dysre-
gulation of cellular signaling pathways, leading to advanced
glycation products and increased reactive oxygen species.
Also, the rise in brain insulin resistance, which could, in part,
lead to increased production of Ab [40], could also result in
decreased glucose transporters and glucose metabolism within
neurons, leading to an upregulation of Grp78.
Metformin, a type 2 diabetes therapy, is a drug that has been
shown to increase glucose uptake in cells. Interestingly, treat-
ment with a metformin dose known not to affect lifespan in
wild-type Drosophila [41] increased the lifespan of Ab-express-
ing flies. In accordance with previous studies [42], we also found
that metformin decreased expression of Grp78, suggesting that
the rescue of Ab toxicity could be due to increased UPR. Metfor-
min’s effect in AD is controversial, with some studies reporting
patient benefits [43] but others finding that it worsened cognitive
performance [44], possibly related to metformin’s ability to
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Figure 5. Glut1 Reduces Accumulation of
Insoluble Ubiquitinated Proteins
Western blots of SDS-soluble protein fraction from
the heads of day-17 flies expressing Ab or AbGlut1
in neurons (+RU) and uninduced controls (-RU),
probed for ubiquitinated proteins (FK2) and for
actin, plotted below as means ± SEM (n = 4). The
two blots shown are from different experiments.
*p < 0.05; **p < 0.01, by ANOVA. Genotypes: UAS
Ab; elavGS, UAS Ab/UAS Glut1; elavGS.increase APP levels and processing to increase Ab production
[45]. Our study points to a novel and unexplored role of met-
formin as a modulator of the UPR in neurodegeneration down-
stream of Ab accumulation, which could provide a useful
therapeutic avenue in a clinical context where AD patients
present quite late in disease development and have already
accumulated Ab peptide in their brain.
EXPERIMENTAL PROCEDURES
Fly Husbandry and Stocks
All flies were reared at 25C on a 12-hr:12-hr light:dark (LD) cycle at constant
humidity and on standard sugar-yeast-agar (SYA) medium (agar, 15 g/l; sugar,
50 g/l; autolyzed yeast, 100 g/l; nipagin, 100 g/l; and propionic acid, 2 ml/l).
Adult-onset, neuron-specific expression of UAS constructs was achieved as
described elsewhere [12]. Briefly, 24–48 hr after eclosion, female flies carrying
a heterozygous copy of elavGS and at least one UAS construct were fed SYA
medium supplemented with 200 mMmifepristone (RU486) to induce transgene
expression. For induction with quinic acid (QA), flies were put on food contain-
ing 7.5 g of QA per liter. Metformin was added to the food at the stated con-
centrations. ElavGS was derived from the original elavGS 301.2 line [46] and
obtained as a generous gift from Dr. H. Tricoire (CNRS); the UAS-Ab42Arc
(UAS Ab) stock was a gift from Dr. D. Crowther (University of Cambridge).
The nSyb-QF2 stock was a gift from Dr. C. Potter (Johns Hopkins School
of Medicine) [17]. W1118, tubulin-QS (tub-QS), UAS-Grp78.K97S, UAS-
Xbp1GFP, daughterless-Gal4 (daGal4), Glut1 RNAi line (TRiP.HMS02152)
and Repo-Gal4 were obtained from the Bloomington Drosophila Stock Center.
All transgenes were backcrossed into the w1118 background to ensure a
homogeneous genetic background between transgenic lines. All experiments
were carried out on mated females, unless otherwise stated.
Lifespan Analysis
Flies were raised at standard density in 200-ml bottles. After eclosion, flies
were allowed to mate for 24–48 hr. At least 110–150 females of the appropriate
genotype were split into groups of 15 and housed in vials containing SYA me-
dium with or without drugs. Deaths were scored, and flies tipped onto fresh
food three times a week. Data are presented as cumulative survival curves,
and survival rates were compared using log-rank tests or Cox proportional
hazards performed in JMP (version 9.0) software (SAS Institute). All lifespans
were performed at 25C unless otherwise stated.Current BiologyClimbing Assay
The climbing assay in Figure 1 was performed as
previously described [47]. Briefly, 15 flies were
placed in a 25-cm pipette, tapped to the bottom,
and allowed to climb for 45 s. The number of flies
in the top 5 cm, center, and bottom 3 cm was
scored. A performance index was calculated for
each time point and plotted. Statistical analysis
was performed in R using ordinal logistics regres-
sion, using the individual heights for each fly as
data points. For the climbing assay in Figures 4
and 6, the assay was performed with the following
modifications: 45 flies were housed in a glass-
walled chamber 25 cm tall, and flies were tapped
to the bottom as described earlier and allowed to climb for 20 s before scoring.
The analysis was the same as described earlier.
Western Blotting
Protein samples were prepared by homogenizing in 23 SDS Laemmli sample
(4% SDS, 20% glycerol, 120 mM Tris-HCl [pH 6.8], 200 mM DTT with bromo-
phenol blue) and boiled at 95C for 5 min. Samples were separated on
pre-cast 4%–12% Invitrogen Bis-Tris gels (NP0322) and blotted onto PVDF
(polyvinylidene fluoride) or nitrocellulose membrane (for Grp78) in Tris-glycine
buffer supplemented with 10% ethanol. Membranes were blocked in 5%
milk and 1% BSA in TBS-T (Tris-buffered saline with 0.05% Tween-20) for
1 hr at room temperature (RT) and then incubated with primary antibodies
in block. Ubiquitin westerns were blocked in 1% BSA. Primary antibody
dilutions used were as follows: anti-Grp78, 1:1,000 (Novus Biologicals,
NBP1-06274); anti-actin, 1:10,000 (Abcam, ab1801); anti-Ubiquitin, 1:1,000
(Millipore, FK2); and anti-eIF2A-phospho, 1:1,000 (Cell Signaling, 3597). Sec-
ondaries used were anti-rabbit and anti-mouse (Abcam, ab6789 and ab6721)
at 1:10,000 dilutions for 1 hr at RT. Bands were visualized with Luminata
Forte (Millipore) and imaged with ImageQuant LAS4000 (GE Healthcare
Life Sciences). Quantification was carried out with ImageQuant software or
ImageJ.
Preparation of Detergent-Soluble Fractions for Insoluble
Ubiquitinated Protein Gels
The method was adapted from [48]. Briefly, 10–20 heads were extracted in
75 ml Triton X extraction buffer and spun at 13,000 3 g for 10 min at 4C,
and the supernatant was collected as the Triton X soluble fraction. The pellet
was re-suspended in 50 ml SDS extraction buffer and spun again, and the
supernatant was collected as the SDS soluble fraction. Samples were stored
at 80C and run as described earlier.
qPCR
Total RNAwas extracted from heads or whole flies (for Figure 3) and converted
to cDNA (see Supplemental Experimental Procedures for details). qPCR was
performed using the PRISM 7000 sequence detection system (Applied Bio-
systems). Each sample was analyzed in duplicate, and values are the mean
of three or four independent biological repeats ±SEM.
Quantification of Ab42
Five fly heads were homogenized in 50 ml GnHCl extraction buffer (5 M guani-
dinium HCl, 50 mM HEPES [pH 7.3], 1:10 dilution of protease inhibitor cocktail26, 2291–2300, September 12, 2016 2297
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Figure 6. Metformin Extends the Lifespan of Ab-Expressing Flies
(A) Lifespan survival curves of flies expressing Ab (+RU) and controls (-RU) in the presence of different metformin (Met) concentrations (all the metformin-
treated +RU flies were significantly longer lived than the +RU-alone control: p < E-4 for 5mM, p < E-6 for 10mM, p < E-8 for 20mM, and p < 0.01 for 80mMby log-
rank test).
(B) Climbing assay performance index (PI) for the same flies (p < 1E-5 when comparing the +RU control relative to the +RU flies treated with 20 mM or 80 mM
metformin by ordinal logistics regression).
(C) Ab42 protein levels, measured by ELISA, in the heads of 15-day-old flies expressing Ab (+RU) and controls (-RU) in the presence or absence of 10 mM
metformin, plotted as means ± SEM (n = 3). *p < 0.0001, by ANOVA; ns, not significant.
(D) Lifespan survival curves of flies expressing Ab Glut1 RNAi (+RU) and controls (-RU) in the presence or absence of 10 mM metformin (no difference
between +RU-treated flies by log-rank test). Genotype: wv; UAS Ab; elavGS/Glut1RNAi. (C).
(E) Western blots for Grp78 and actin control in the heads of flies treated with 10 mM meformin, plotted as means ± SEM (n = 4). *p < 0.01, by ANOVA; ns, not
significant.
Genotype for (A)–(C) and (E): UAS Ab; elavGS.[Sigma, P8340], and 5 mM EDTA) and centrifuged at 21,000 3 g for 5 min at
4C, and cleared supernatant was retained as the total fly Ab42 sample.
Ab42 was measured with an ELISA kit (Millipore, EZHS42), according to the
manufacturer’s instructions, and protein was measured with a Bradford assay2298 Current Biology 26, 2291–2300, September 12, 2016(Bio-Rad protein assay reagent), and the amount of Ab42 in each sample was
expressed as a ratio of the total protein content (picograms per microgram of
total protein). Data are expressed as the mean ± SEM obtained from three bio-
logical repeats for each genotype.
Microscopy
Brains were dissected in 4% paraformaldehyde in PBS with Tween 20 (PBST),
incubated for 20 min, rinsed in PBST, mounted in Vectashield with DAPI, and
imaged on a Zeiss LSM510 inverted confocal microscope. Images were taken
on the203or403objective as stacksandareshownasmaximum intensitypro-
jections of the complete stack. The same size stacks were taken for experi-
mental and control samples. All images for one experiment were taken at the
same settings. For Xbp1fluorescence (in Figure 2C), total fluorescence intensity
of a given area of the brain was measured with ImageJ. Values shown are the
averages for 6–13 brains ± SEM. Samples were compared by ANOVA. For
neuronal Tomato, imageswere blind scored andgiven a score from1 to 5 based
on fluorescent intensity; average scores are presented with their SEM (n = 3–5).
Analysis of Activity and Sleep
Individual, 21-day-old, mated female flies were placed in glass tubes (65mm3
5 mm) containing standard 13 SYA, and activity was recorded using the DAM
System (Drosophila Activity Monitoring System; TriKinetics) as described pre-
viously [49]. Flies were entrained to a 12-hr:12-hr light:dark (LD) cycle at 25C
and 65% humidity 24–36 hr before recording. 5 days of the 12:12 hr LD cycle
were recorded, followed by 5 days of a 12-hr:12-hr dark:dark (DD) cycle. Anal-
ysis of locomotor activity was performed using the fly toolbox and MATLAB
software (MathWorks), as described previously [50]. Sleep was defined as a
bout of inactivity lasting 5 min or more, and sleep analysis was performed
with pySOLO [51]. All behavioral data (activity and sleep duration) are repre-
sented by mean values with their SEM.
Tunicamycin Stress Assay
Flies were tipped into vials containing 1% agar, 1.5% sucrose, and 10 mg/l of
tunicamycin. Dead flies were scored at regular intervals, and lifespan curves
were compared with log-rank test.
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